Ali Rezai (neurosurgeon)

Ali R. Rezai (born 1965) is an Iranian-born American neurosurgeon and neuroscientist. His work and research has focused on neuromodulation treatments for patients with neurological and mental health conditions, including neuromodulation techniques such as deep brain stimulation (DBS) through brain chip implants to treat Parkinson's disease tremors, obsessive–compulsive disorder, Alzheimer's disease, traumatic brain injury, spinal cord injury, and addiction. Recent research since 2020 has focused on deep brain stimulation for addiction treatment, as well as focused ultrasound to treat tremor, addiction and Alzheimer's disease. He currently serves as West Virginia University's Associate Dean of Neuroscience, as well as Executive Chair of the Rockefeller Neuroscience Institute. Earlier in his career, he served as director of New York University's Center for Functional and Restorative Neurosurgery until 2000. He then served as director of the functional neurosurgery program at the Cleveland Clinic until 2009, when he became director of Ohio State University's Neurological Institute. He is the former president of the Congress of Neurological Surgeons, the North American Neuromodulation Society, and the American Society of Stereotactic and Functional Neurosurgery, and serves on the editorial board of several scientific journals including ''Neurosurgery''.

In January 2024, Rezai and a team at RNI published findings in ''The New England Journal of Medicine'' showing that opening of the blood-brain barrier using focused ultrasound increased removal of amyloid-beta (Aβ) plaques in Alzheimer’s disease patients undergoing anti amyloid-beta (Aβ) antibody treatment. The study found that the ultrasound in combination with antibody treatment increased Alzheimer’s plaque removal by 53% more in 6 months as compared to antibody treatment alone. ''60 Minutes'' featured the research, Rezai, and his team in two news spots later that month. Provided by Wikipedia